Virginia Piper Cancer Institute® , we are dedicated to providing patients and families with exceptional care and service, with access to the most advanced treatment and research options.
The Institute includes program committees designed to drive Allina Health's vision for best clinical practice and will guide clinical program development through system integration. The programs are in place to ensure patients receive consistently high quality care with an exceptional patient experience across Allina Health and the continuum of care.
Consensus guidelines are comprehensive in describing the rationale for these recommendations and references to support them. We believe we have been thorough in putting them together through the experts we have in our community of expert oncology physicians.
The following best practice consensus guidelines have been implemented by
Allina Health's Oncology Clinical Service Line:
Ductal Carcinoma In Situ (DCIS): Management of surgical margins and recommendations for margin re-excisions in patients having breast conserving therapy
Identification of patients or family members at high risk for inherited gynecologic cancers
Identification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation
Invasive carcinoma: Management of margins, and recommendations for margin re-excisions in patients having breast conserving therapy
Ordering breast cancer oncotype DX assay
Mammography screening for women at average risk for breast cancer
Pathological evaluation of the axillary sentinel lymph nodes in patients undergoing lumpectomy and radiation therapy
Post-mastectomy radiation for patients with 1-3 + lymph nodes
Whole breast hypofractionation
Use of imaging in colon cancer
Sequence of colon cancer work up
Sequence of esophageal and gastric cancer work up
the diagnosis of lung cancer and adequate tissue samples
Imaging for central nervous system staging in non-small cell lung cancer
Management of IIIA (N2) non-small cell lung cancer (NSCLC)
Treatment of stage 1 lung cancer
Post stereotactic ablative radiotherapy (SABR) follow-up
Hepatocellular carcinoma surveillance
Hepatitis C screening guidelines